Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Community Practice Connections: Making the Most of Effective Antithrombotic Strategies in Patients with CAD and PAD

Release Date: December 17, 2021
Expiration Date: December 17, 2022

Activity Overview

Effective management of high-risk patients with coronary artery disease (CAD) and peripheral artery disease (PAD) is essential for decreasing major adverse events such as myocardial infarction, stroke, limb amputations, and death. Recent studies evaluating antithrombotic strategies such as dual antiplatelet therapy and dual pathway inhibition (DPI) have shown that DPI is an effective strategy in reducing these major adverse events in high-risk patients.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the satellite symposium Cases and Conversations™: Making the Most of Effective Antithrombotic Strategies in Patients with CAD and PAD, presented at the 2021 American Heart Association Annual Scientific Sessions. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with CAD and PAD, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward cardiologists and cardiology subspecialists involved in the care of patients with or at risk for atherosclerotic disease. Nurse practitioners, physician assistants, nurses, and other health care professionals interested in the treatment of atherosclerotic disease are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss the pathophysiology of atherosclerosis
Describe the rationale for novel secondary prevention antithrombotic strategies in high-risk patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
Evaluate the efficacy and safety of antithrombotic strategies in patients with CAD and/or PAD to mitigate cardiovascular risk
Develop strategies to overcome challenges in reducing the risk of secondary events in patients with PAD and/or CAD

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Chair

Kelley Robert Branch, MD, MS
Professor of Medicine
Director, Cardiovascular Clinical Trials
Associate Director, Clinical Trials Service Unit
UW School of Medicine
Attending Physician
University of Washington Medical Center
Seattle, WA

Disclosures: Grant/Research Support: Bayer AG, Eli Lilly and Co, Novartis, Sanofi Genzyme; Consultant: Bayer AG, Janssen Pharmaceuticals, Kestra Medical Technologies Inc, Sana Biotechnology.

Faculty

Sonia Anand, MD, PhD
Professor of Medicine and Epidemiology
Tier 1 Canada Research Chair
Director, Population Genomics Program
HSF/Michael G. DeGroote Chair in Population Health Research
McMaster University
Hamilton, Ontario, Canada

Disclosures: Grant/Research Support: Bayer AG, Janssen Pharmaceuticals; Consultant: Bayer AG, Janssen Pharmaceuticals.

Schuyler Jones, MD
Associate Professor of Medicine and Population Health Sciences
Medical Director, Duke Heart Center Clinical Research Unit
Director, Duke University Cardiac Catheterization Laboratory
Duke University School of Medicine
Durham, NC

Disclosures: Grant/Research Support: Bayer AG, Boehringer Ingelheim, Merck & Co Inc, National Institutes of Health, Patient-Centered Outcomes Research Institute; Consultant: Bayer AG, Bristol Myers Squibb, Janssen Pharmaceuticals.

Christian Thomas Ruff, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Director, General Cardiology, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

Disclosures: Grant/Research Support: Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, National Institutes of Health; Consultant: Anthos Therapeutics, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Pfizer Inc.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.